The clinical application of the ErbB2 specific CAR T cells with the herceptin derived 4D5 scFv binding domain, produced fatal side effects [23], most likely due to the off-tumor on-target activation of the CAR T cells against the healthy tissues with physiological ErbB2 levels. The gene discussed is ERBB2; the disease is neoplasm.